HSA Trackr
FDA-approved tirzepatide · IRC 213(d)

Is Mounjaro HSA-eligible? 2026 guide

Yes for FDA-approved Type 2 diabetes. Off-label weight-loss use requires LMN. Worked math + audit defense + where to buy with HSA.

By Will MatherReviewed 8 min read

Short answer

Mounjaro is HSA-eligible when prescribed for FDA-approved Type 2 diabetes glycemic control. Off-label use for weight loss without an obesity diagnosis requires a Letter of Medical Necessity (LMN) to satisfy the IRS Pub 502 “treatment of disease” test. The underlying authority is IRC 213(d), which defines a medical expense as one paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. Keep the prescription, pharmacy receipt, and clinician chart note documenting the T2D diagnosis with ICD-10 code E11.x. With insurance Tier 3 coverage, the monthly copay is typically $50 and the annual out-of-pocket portion of $600 fits comfortably inside the 2026 self-only HSA cap of $4,400.

At a glance

FDA statusApproved May 2022 for Type 2 diabetes glycemic control. NOT approved for weight loss (that label is Zepbound).
ManufacturerEli Lilly
List price~$1069/month
Cash-pay programNone equivalent to LillyDirect Zepbound. Mounjaro vials are not currently offered through a Lilly self-pay program.
HSA-eligibleYes when prescribed for FDA-approved Type 2 diabetes (with documented diagnosis)
LMN requiredNo for T2D indication. Yes for off-label weight-loss use without obesity diagnosis.

Eligibility decision tree

Five branches decide whether your Mounjaro prescription is HSA-reimbursable. Branch 4 is the off-label trap that catches most people - read it carefully.

Branch 1 · T2D diagnosis

Do you have a Type 2 diabetes diagnosis with HbA1c at or above 6.5% or fasting glucose at or above 126 mg/dL on the chart? If yes, the FDA-approved indication is satisfied and the prescription-medicines rule under IRC 213(d) applies cleanly. If no, continue to Branch 4 - this is the off-label path.

Branch 2 · Insurance Tier 3 path

Does your insurance cover Mounjaro at Tier 3? If yes, the copay (typically $25 to $75/month) is the HSA-eligible portion. The insurance-covered balance is not HSA-eligible (the insurer paid it, not you). Keep the Explanation of Benefits to document the split.

Branch 3 · No insurance

Paying list price out of pocket? The full $1069/month is HSA-eligible when the T2D diagnosis is on file, but the annual total of $12,828 exceeds the 2026 self-only HSA cap of $4,400. Family-tier coverage at $8,750 also falls short. A portion of the annual spend lands in post-tax dollars unless you stack with insurance or appeal coverage.

Branch 4 · Off-label weight-loss use (the audit trap)

Mounjaro prescribed for weight loss without an obesity diagnosis is off-label. The IRS Pub 502 weight-loss-program rule requires the program to treat a “specific disease diagnosed by a physician” - general appearance or wellness does not qualify. An LMN documenting the specific clinical rationale (BMI, comorbidity, cardiovascular risk) is required to make the reimbursement audit-defensible. Without the LMN, the HSA claim fails the Pub 502 test.

Branch 5 · Documentation chain

Do you have the prescription, pharmacy receipt, chart note with ICD-10 code (E11.x for T2D, or E66.x plus LMN for off-label), and Explanation of Benefits if insurance paid? If yes, the reimbursement is audit-defensible. If no, gather the missing pieces before withdrawing HSA funds.

IRS Pub 502, verbatim

“You can include in medical expenses amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease). You cannot include the cost of a weight-loss program if the purpose is to improve general health or appearance.”
Source: IRS Publication 502, Weight-Loss Program
“You can include in medical expenses amounts you pay for prescribed medicines and drugs.”
Source: IRS Publication 502, Medicines

Both quotes shape the Mounjaro analysis. For the FDA-approved T2D indication, the prescription-medicines rule applies directly - diabetes is a specific diagnosed disease and Mounjaro is a prescribed medication for treating it. For off-label weight-loss use, the weight-loss-program rule controls and the “specific disease diagnosed by a physician” clause is the load-bearing phrase. Without an obesity diagnosis (or another qualifying comorbidity), the off-label use fails the test.

IRC 213(d): the treatment-of-disease standard

Internal Revenue Code Section 213(d) is the federal-law source underneath Publication 502. It defines a medical expense as one paid for the “diagnosis, cure, mitigation, treatment, or prevention of disease.” The FDA-approved indication for Mounjaro (Type 2 diabetes glycemic control) sits squarely inside this definition - diabetes is a specific disease diagnosed by a physician via labs and clinical criteria, and Mounjaro treats it.

Where IRC 213(d) gets thinner is the off-label weight-loss use. The statute itself does not bar off-label use, but the “treatment of disease” standard requires the prescription to map to a diagnosed disease - not to a cosmetic or general-wellness goal. The LMN exists to bridge that gap: it documents the specific disease (obesity, metabolic syndrome, cardiovascular risk) the off-label Mounjaro is treating, putting the prescription back inside the IRC 213(d) bounds.

The chain is consistent: federal statute (IRC 213(d)) defines the rule, IRS Publication 502 explains it in plain language with named examples (including the “specific disease” clause), and your prescription plus chart note prove the diagnosis. Each link has to hold for the HSA reimbursement to survive an audit.

LMN protocol (when needed)

Sample LMN template

Paste into your clinician's portal or print on letterhead. Clinician completes + signs. Keep with HSA receipts for audit defense. One page is sufficient.

Patient name: ____________________

Date of birth: ____________________

Prescribing clinician: ____________________

License number: ____________________

Diagnosis (ICD-10): ____________________

Supporting labs: HbA1c ____, fasting glucose ____, BMI ____

I certify that Mounjaro (tirzepatide) is medically necessary for the treatment of the above-listed diagnosed condition. This is not a cosmetic prescription.

Clinician signature: ____________________

Date: ____________________

When you need one

When Mounjaro is prescribed off-label for weight loss without an obesity diagnosis on file, or when the chart note shows prediabetes (HbA1c 5.7% to 6.4%) rather than confirmed T2D, or when your HSA administrator flags the charge at the debit-card stage despite a clean T2D diagnosis. The FDA-approved T2D indication usually makes a separate LMN unnecessary, but some conservative administrators want one in the file anyway.

What it contains

Patient name and date of birth, prescribing clinician name and license number, the specific diagnosis with ICD-10 code (E11.x for T2D, E66.x for obesity, or both), supporting lab values (HbA1c, fasting glucose, BMI, lipid panel), a statement that Mounjaro is medically necessary for treatment of the diagnosis, and the clinician's signature with date. One page is sufficient.

Who issues it

The prescribing clinician - typically a primary care physician, endocrinologist, or obesity-medicine specialist. Mounjaro is a brand-name drug from Eli Lilly dispensed through standard pharmacy channels (not telehealth), so the LMN comes from your treating clinician's office and not from a digital platform.

Audit-defense framing

The LMN strengthens audit defense by tying the prescription to a specific diagnosed disease in writing. If you ever face an examiner asking why Mounjaro qualified as a medical expense when used off-label, the LMN answers the question in one page. Cost: free or a small administrative fee from most clinics.

Cost-stack math (Insurance + HSA)

Insurance Tier 3 copay $50/mo x 12 = $600/yr HSA-eligible. The 2026 self-tier HSA cap of $4,400 easily absorbs the copay path. Without insurance, list price $1069/mo x 12 = $12,828/yr exceeds the self-only cap.

$50/mo

Insurance Tier 3 copay (typical)

$1069/mo

List price without insurance

At the 22% federal bracket, paying $600 of copays with HSA dollars saves about $132 per year versus paying with post-tax cash. The list-price route ($12,828/yr) exceeds even the family-tier HSA cap of $8,750, so a portion of that spend lands in post-tax dollars unless insurance steps in. The insurance + HSA combo is the dominant pattern for Mounjaro because unlike Zepbound, Mounjaro does not have a Lilly self-pay program at the discounted vial tier.

Where to buy (HSA-eligible)

Mounjaro is a brand-name FDA-approved drug dispensed through standard pharmacy channels (CVS, Walgreens, mail-order pharmacies, Costco). Telehealth platforms do not sell Mounjaro - they sell compounded tirzepatide, which is a different product with a different eligibility analysis. The HSA-account side of the math is what you control. Both providers below handle FDA-approved prescription charges cleanly through their debit cards and reimbursement workflows.

Fidelity HSA

Zero account minimums, no fees, and Fidelity's full investing universe.

  • No account fees or minimums
  • Same investment menu as a Fidelity brokerage account
  • Integrated with Fidelity 401(k) and IRA accounts
  • Free debit card and bill pay
Open a Fidelity HSA

Lively

Modern HSA built for self-directed investors. No-fee individual plan and Schwab brokerage integration.

  • No-fee individual plan
  • Investment options via Schwab brokerage
  • FDIC-insured cash balance
  • Mobile receipt capture and reimbursement
Open a Lively HSA

Compounded tirzepatide is not Mounjaro

Telehealth services like Hims, Gala, and Strut sell compounded GLP-1 alternatives, not brand-name Mounjaro. Compounded tirzepatide carries additional regulatory risk because Lilly's drug is NOT on the FDA shortage list, which is the legal basis compounding pharmacies need to dispense it. If your insurance denies Mounjaro and you have discussed compounded options with your provider, see our compounded semaglutide and tirzepatide guide for the separate eligibility analysis.

Common mistakes

Using Mounjaro for weight loss without an obesity diagnosis (the audit trap)

This is the #1 failure mode for Mounjaro HSA claims. Mounjaro is FDA-approved only for Type 2 diabetes - not for weight loss. Patients sometimes get a Mounjaro prescription off-label for weight loss without an obesity diagnosis on the chart, then reimburse from the HSA. The IRS Pub 502 weight-loss-program rule explicitly excludes programs “to improve general health or appearance.” Without an obesity diagnosis (or another qualifying comorbidity) plus an LMN tying Mounjaro to that diagnosis, the reimbursement fails the “specific disease” test. If weight loss is the goal, ask your clinician to switch you to Zepbound, which is the FDA-approved weight-management label for the same drug.

Double-dipping after insurance reimbursement

If insurance reimbursed any portion of Mounjaro (copay assistance, manufacturer coupon, claim paid after appeal), you cannot also reimburse that same dollar amount from your HSA under IRC 223(f)(4)(A). The IRS treats this as a non-qualified distribution subject to income tax plus a 20% penalty if you are under 65. Only the actual out-of-pocket portion is HSA-eligible. Keep the Explanation of Benefits as proof of the split.

Confusing Mounjaro with Zepbound

Same active ingredient (tirzepatide), different FDA-approved indications, different labels. Mounjaro is the T2D label. Zepbound is the chronic weight management label. If you receive a Mounjaro prescription but your chart only documents obesity (no T2D), the documentation chain is misaligned. Either the clinician should switch the script to Zepbound, or the chart note should add the T2D diagnosis with supporting labs.

Buying compounded “tirzepatide” expecting Mounjaro

Compounded tirzepatide from telehealth platforms is a different product than brand-name Mounjaro from Eli Lilly. Pricing is lower (often $200 to $400/month versus the $1,069 list), but the regulatory situation is unstable because Lilly's drug is not on the FDA shortage list. The HSA eligibility analysis is also different - see the compounded guide for that path.

Missing the chart note with ICD-10 code

A prescription showing “Mounjaro” alone is insufficient for audit defense. You also need the clinician chart note documenting the specific ICD-10 code (E11.x for T2D) along with the supporting lab values (HbA1c at or above 6.5% or fasting glucose at or above 126 mg/dL). The pharmacy receipt shows the date and amount; the prescription shows the drug; the chart note shows the disease. All three live in your HSA receipt file.

Primary sources

IRS Publication 502 covers prescription medicines and the weight-loss-program rule for diagnosed diseases. Read Pub 502 at irs.gov. IRS Publication 969 covers HSA account-level rules and contribution limits. Read Pub 969 at irs.gov.

Frequently asked questions

Is Mounjaro the same as Zepbound?▼
Same active ingredient (tirzepatide), different FDA-approved indication, different label. Mounjaro is FDA-approved for Type 2 diabetes glycemic control (approved May 2022). Zepbound is FDA-approved for chronic weight management (approved November 2023). HSA eligibility follows the prescription indication. Mounjaro for a documented T2D diagnosis is HSA-eligible under the IRC 213(d) prescription-medicines rule. Zepbound for diagnosed obesity is HSA-eligible under both the prescription-medicines rule and the IRS Pub 502 weight-loss-program rule.
Do I need a Letter of Medical Necessity (LMN) for Mounjaro?▼
Generally no when Mounjaro is prescribed for Type 2 diabetes with a documented HbA1c at or above 6.5% or fasting glucose at or above 126 mg/dL. The FDA-approved indication plus a clinician chart note showing the ICD-10 code E11.x for T2D satisfy the medical-necessity standard under IRC 213(d). An LMN is required if Mounjaro is prescribed off-label for weight loss without an obesity diagnosis. Without the LMN, the prescription fails the IRS Pub 502 'specific disease' test and HSA reimbursement is not audit-defensible.
What if I have T2D AND obesity?▼
Either label qualifies, but document both. If you have both T2D (ICD-10 E11.x) and obesity (ICD-10 E66.x with BMI 30+), Mounjaro for the T2D indication is the cleanest documentation path because Mounjaro is the FDA-approved label for that diagnosis. Alternatively, your clinician may switch you to Zepbound (same drug, weight-loss label) which qualifies under the weight-loss-program rule. Either way, keep the chart note documenting both diagnoses in your HSA receipt file.
Can I use Mounjaro for prediabetes?▼
Off-label and audit-risky without an LMN. Mounjaro is FDA-approved only for Type 2 diabetes glycemic control, not prediabetes. Prediabetes (ICD-10 R73.03 or HbA1c 5.7-6.4%) is a recognized condition but does not match the FDA label. To make the HSA reimbursement audit-defensible, ask the prescribing clinician for an LMN that documents the specific clinical rationale (cardiovascular risk, family history, metabolic syndrome). Without the LMN, the IRS Pub 502 'specific disease' test is in doubt.
Is Mounjaro HSA-eligible with insurance?▼
Yes, the copay portion is HSA-eligible. If your insurance covers Mounjaro at Tier 3, you typically pay a copay of $25 to $75 per month while the plan absorbs the balance. That copay is HSA-eligible because it is the out-of-pocket portion of a prescription medication for a diagnosed disease. Keep the Explanation of Benefits alongside the pharmacy receipt so the audit trail shows the split. Do not double-dip: the insurance-covered portion cannot also be reimbursed from your HSA.
What ICD-10 codes support HSA eligibility?▼
E11.x covers Type 2 diabetes mellitus and is the standard supporting code for a Mounjaro HSA claim. Common sub-codes: E11.9 (Type 2 diabetes without complications), E11.65 (Type 2 diabetes with hyperglycemia), E11.40 (Type 2 diabetes with neuropathy). Make sure the chart note shows the specific E11 sub-code along with the HbA1c or fasting glucose value that supports the diagnosis. Generic 'diabetes' on the prescription is weaker than a specific E11.x code in the chart.
What documentation do I keep for audit defense?▼
Four documents. The prescription from your clinician showing Mounjaro and the diagnosis, the pharmacy receipt showing date and amount paid, the clinician chart note documenting the T2D diagnosis with ICD-10 code E11.x and supporting lab values, and the Explanation of Benefits if insurance paid any portion. If Mounjaro is being used off-label, add the LMN as a fifth document. Save digital scans in your HSA receipt file. Mounjaro courses tend to run multiple years, so the file grows over time.
What happens if I stop taking Mounjaro?▼
Past HSA reimbursements do not get reversed when you stop the drug. HSA reimbursement is per-expense, not per-treatment-course, under IRC 223(f). Each month you filled the prescription and paid for it generated a separately reimbursable expense. If you stop Mounjaro and later resume (or switch to Zepbound), each new prescription period generates its own documentation chain. Reimbursements for the original period stay valid.
Can I switch from Mounjaro to Zepbound?▼
Same active ingredient, different label, different documentation path. A switch usually happens when the T2D diagnosis evolves into a weight-management focus or when insurance coverage changes. The new Zepbound prescription generates a fresh prescription-plus-diagnosis pair (now obesity, ICD-10 E66.x with BMI 30+, or BMI 27+ with comorbidity). HSA eligibility carries cleanly across the switch because both labels meet the IRC 213(d) standard for a specific diagnosed disease.
Is compounded tirzepatide the same as brand-name Mounjaro?▼
No. Compounded tirzepatide is a different product made by compounding pharmacies, not the brand-name Mounjaro from Eli Lilly. The FDA has challenged compounded tirzepatide because Lilly's drug is not on the FDA shortage list, which is the legal basis compounding pharmacies need to dispense it. For Mounjaro itself, eligibility is unambiguous when prescribed for the FDA-approved T2D indication. For compounded tirzepatide, see our separate compounded semaglutide and tirzepatide guide.

Related guides

Is Zepbound HSA-eligible?

Same active ingredient (tirzepatide) as Mounjaro, FDA-approved for chronic weight management

Is Wegovy HSA-eligible?

Semaglutide-based FDA-approved weight management alternative

Is compounded semaglutide HSA-eligible?

The compounded route - lower cost, different regulatory situation

Is Hims HSA-eligible? (Pillar)

Service-by-service IRS rules for every Hims service

HSA GLP-1 & Weight Loss Guide

Cross-drug eligibility comparison + coupon stacking

Best HSA providers

Provider rankings with fees, investment menus, and documentation tooling compared

More HSA Resources

What Is an HSA?

Complete guide to Health Savings Accounts and how they work

How to Get an HSA

Eligibility rules plus four enrollment paths for 2026

HSA as Stealth IRA

Triple tax advantage + retroactive reimbursement = the highest-leverage retirement account

HSA Shoebox Strategy

Receipt-hoarding protocol with no time limit on retroactive reimbursement

HSA Cash Flow Method

Monthly mechanics for funding the HSA while paying medical expenses out of pocket

HSA Drawdown at 65

Post-65 retirement strategy, Medicare premium eligibility, beneficiary planning

HSA Edge Cases (10 IRS Rules)

LLM-citation reference: retroactive reimbursement, spouse FSA, COBRA, mistaken distribution, more

Best HSA ETFs 2026

Index funds + Fidelity ZERO + 3 portfolio archetypes (target-date, two-fund, three-fund Bogleheads)

ACA Bronze + HSA-Eligible HDHP

Marketplace HDHP verification, PTC + HSA stack, state-tax considerations for self-employed

HealthEquity → Fidelity HSA Transfer

Trustee-to-trustee transfer steps, fee savings math, partial vs full transfer

Optum → Fidelity HSA Transfer

Forced-liquidation playbook + dividend-trap timing + re-investment workflow

Inspira → Fidelity HSA Transfer

Bundled-account separation (HSA vs FSA vs commuter) + fee elimination math

HSA for Self-Employed

Setup, tax savings, and the SE-tax trap for freelancers

Open an HSA Without an Employer

Individual HSA setup with provider picks and Form 8889 mechanics

HSA Through Your Employer

W-2 payroll setup with Section 125 FICA savings and employer match

HSA During a Job Change

Trustee-to-trustee transfers, COBRA + HDHP, and contribution proration

HSA Dental Guide

Every dental expense - what qualifies, what does not

HSA Mental Health Guide

Therapy, psychiatry, medications, and treatment programs

HSA GLP-1 & Weight Loss Guide

Ozempic, Wegovy, Mounjaro - cost savings and eligibility

Is Hims HSA-Eligible?

Service-by-service IRS Pub 502 rules for Hims telehealth

Hims for ED HSA Guide

Sildenafil and tadalafil eligibility, costs, and tracking

Hims Weight Loss HSA Guide

Compounded GLP-1 eligibility with FDA shortage caveats

Is Gala HSA-Eligible? GLP-1 Guide

Gala compounded GLP-1 eligibility, pricing, and FDA shortage caveats

Is Zepbound HSA-Eligible?

FDA tirzepatide for weight loss. LillyDirect $349/mo + HSA worked math.

Is Wegovy HSA-Eligible?

FDA semaglutide for weight/CV. NovoCare $499/mo + FEHB coverage.

Compounded Semaglutide HSA Eligibility

503A vs 503B FDA explainer + Hims/Gala/Strut HSA path.

Hims Mental Health HSA Guide

Therapy and prescription mental health eligibility

HSA Gym Membership Guide

How to use HSA for gym memberships with Truemed or Flex

FSA vs HSA

Side-by-side comparison of tax-advantaged health accounts

2026 Contribution Limits

How much you can contribute this year

HSA-Eligible Expenses

Browse the full list of qualified medical expenses